CeY-B1
CeY-B1 is a ceramide analog. CeY-B1 inhibits the proliferation, migration and invasion of cervical cancer cells, induces apoptosis and cell cycle arrest. CeY-B1 upregulates ASK1, promotes the phosphorylation of JNK, downregulates Bcl‑2, and inhibits the PI3K/AKT pathway. CeY-B1 suppresses tumor growth in cervical cancer xenograft mouse models. CeY-B1 can be used for relevant research on cervical cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2376783-79-6
- Formule: C21H44N2O4
- Masse moléculaire:388.59
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Size
Prix
Stock
Quantité
Amount: USD 0.00
Please select quantity
or
or
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
CeY-B1 is a ceramide analog. CeY-B1 inhibits the proliferation, migration and invasion of cervical cancer cells, induces apoptosis and cell cycle arrest. CeY-B1 upregulates ASK1, promotes the phosphorylation of JNK, downregulates Bcl‑2, and inhibits the PI3K/AKT pathway. CeY-B1 suppresses tumor growth in cervical cancer xenograft mouse models. CeY-B1 can be used for relevant research on cervical cancer[1].
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| SiHa | IC50 |
25 μM
|
Inhibition of cell viability against human SiHa cervical cancer cells assessed by CCK-8 assay after 48 h of incubation.
Inhibition of cell viability against human SiHa cervical cancer cells assessed by CCK-8 assay after 48 h of incubation.
|
41904495 |
| HeLa | IC50 |
5.25 μM
|
Inhibition of cell viability against human HeLa cervical cancer cells assessed by CCK-8 assay after 48 h of incubation.
Inhibition of cell viability against human HeLa cervical cancer cells assessed by CCK-8 assay after 48 h of incubation.
|
41904495 |
In Vitro
Anti-cancerApoptosisCell Cycle RegulationLipid Metabolism
Anti-cancer
CeY-B1 (0-160 µM; 48 h) inhibits the viability of SiHa cervical cancer cells with an IC50 of approximately 25 µM; it also inhibits the viability of HeLa cervical cancer cells with an IC50 of 5.25 µM[1].
CeY-B1 (10-20 µM; 48 h) inhibits the proliferation, migration and invasion of SiHa and HeLa cells[1].
CeY-B1 (10-20 µM; 48 h) inhibits the proliferation, migration and invasion of SiHa and HeLa cells[1].
Anti-cancer
Apoptosis
CeY-B1 (5-20 µM; 48 h) induces apoptosis in SiHa and HeLa cells, and this effect is partially mediated by the JNK pathway[1].
CeY-B1 (20 µM) upregulates the mRNA expression of ASK1 and JNK in SiHa cervical cancer cells, and downregulates the mRNA expression of Bcl-2 and cytochrome C, suggesting that the ASK1-JNK axis is activated while anti-apoptotic signals are inhibited[1].
CeY-B1 (10-20 µM) activates the JNK/c-Jun pathway, downregulates Bcl-2, and inhibits the PI3K/AKT pathway in SiHa cervical cancer cells; it activates the JNK/c-Jun pathway and inhibits the PI3K/AKT pathway in HeLa cervical cancer cells, thereby promoting cell apoptosis[1].
CeY-B1 (20 µM) upregulates the mRNA expression of ASK1 and JNK in SiHa cervical cancer cells, and downregulates the mRNA expression of Bcl-2 and cytochrome C, suggesting that the ASK1-JNK axis is activated while anti-apoptotic signals are inhibited[1].
CeY-B1 (10-20 µM) activates the JNK/c-Jun pathway, downregulates Bcl-2, and inhibits the PI3K/AKT pathway in SiHa cervical cancer cells; it activates the JNK/c-Jun pathway and inhibits the PI3K/AKT pathway in HeLa cervical cancer cells, thereby promoting cell apoptosis[1].
Anti-cancer
Cell Cycle Regulation
CeY-B1 (10-20 µM; 48 h) induces S-phase cell cycle arrest in SiHa cervical cancer cells and G2/M-phase cell cycle arrest in HeLa cervical cancer cells[1].
Anti-cancer
Lipid Metabolism
CeY-B1 (25.6 µM; 48 h) alters lipid metabolism in SiHa cells, specifically by inducing the accumulation of pro-apoptotic ceramides and activating the sphingolipid signaling pathway[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Proliferation Assay[1]
-
Cell Line:SiHa cervical cancer cells, HeLa cervical cancer cells
-
Concentration:20 µM (SiHa cells); 10 µM (HeLa cells)
-
Incubation Time:48 h
-
Result:Significantly reduced colony formation ability of SiHa and HeLa cells.
Indicated inhibition of cervical cancer cell proliferation.
Cell Migration Assay [1]
-
Cell Line:SiHa cervical cancer cells, HeLa cervical cancer cells
-
Concentration:20 µM (SiHa cells); 10 µM (HeLa cells)
-
Incubation Time:24 h
-
Result:Significantly reduced cell migration distance compared to control in both SiHa and HeLa cells.
Cell Invasion Assay[1]
-
Cell Line:SiHa cervical cancer cells, HeLa cervical cancer cells
-
Concentration:20 µM (SiHa cells); 10 µM (HeLa cells)
-
Incubation Time:48 h
-
Result:Significantly reduced the number of migrated SiHa and HeLa cells compared to control.
Significantly reduced the number of invaded SiHa cells compared to control.
Resulted in migrated cell number in the control group being approximately twice that in the CeY-B1 group.
Apoptosis Analysis[1]
-
Cell Line:SiHa cervical cancer cells, HeLa cervical cancer cells
-
Concentration:20 µM (SiHa cells); 10 µM (HeLa cells)
-
Incubation Time:48 h
-
Result:Significantly increased the apoptosis rate of SiHa and HeLa cells.
Had its induced apoptosis in both cell lines significantly reduced by treatment with JNK inhibitor.
Apoptosis Analysis[1]
-
Cell Line:SiHa cervical cancer cells, HeLa cervical cancer cells
-
Concentration:5, 10, 20 µM
-
Incubation Time:48 h
-
Result:Increased the apoptosis rate of SiHa and HeLa cells significantly with higher concentrations, as measured by the percentage of Hoechst-positive cells.
Cell Cycle Analysis[1]
-
Cell Line:SiHa cervical cancer cells, HeLa cervical cancer cells
-
Concentration:20 µM (SiHa cells); 10 µM (HeLa cells)
-
Incubation Time:48 h
-
Result:Led to a significant increase in the proportion of SiHa cells in the S phase (S-phase arrest).
Caused significant accumulation of HeLa cells in the G2/M phase (G2/M-phase arrest).
In Vivo
Anti-cancerOthers
Anti-cancer
CeY-B1 (10 mg/kg; i.p.; twice weekly; 3 weeks) suppresses cervical cancer subcutaneous xenograft growth in BALB/c nude mice, reducing tumor volume, tumor weight, tumor cell proliferation, and angiogenesis[1].
Others
CeY-B1 (0.02-2 g/kg; p.o.; single dose) show no acute toxicity in C57BL/6J female mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; twice weekly; 3 weeks
-
Result:Significantly reduced tumor volume and tumor weight compared to control.
Showed increased tumor necrosis, reduced tumor cell density, and reduced nuclear atypia in treated tumors via H&E staining.
Significantly reduced expression of proliferation marker Ki-67 and angiogenesis marker CD31 in treated tumors via immunohistochemical staining.
-
Animal Model:C57BL/6J female mice[1]
-
Dosage:0.02 g/kg; 0.2 g/kg; 2 g/kg
-
Administration:p.o.; single dose
-
Result:Showed no significant difference in mouse body weight compared to control.
Showed no significant difference in organ coefficients of liver, kidney, lung, and heart compared to control.
Showed no significant difference in gross morphology or tissue structure of liver, kidney, lung, and heart compared to control.
Showed no significant difference in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels compared to control.
Related Protocols :
- Western Blot
- Annexin V plus membrane-impermeant dye apoptosis staining
- Cell migration
- BrdU Incorporation Assay
- Patient-Derived Orthotopic Xenograft (PDOX)
- Protocol for Cell Cycle
- Cell Viability Determination by MTT Colorimetric Assay
- Kinase activity and phosphorylation assays
- Detection of Apoptosis
- TUNEL staining for apoptotic DNA fragmentation
- Flow cytometric DNA-content cell-cycle staining
- Patient-Derived Xenograft (PDX)
- Apoptosis Solutions
- Cell invasion
- Splenic/Portal-Vein Liver Metastasis Xenograft
- Protocol for Kinase activity and phosphorylation assays
- Subcutaneous Cell-Line-Derived Xenograft
- Orthotopic Cell-Line Xenograft
- Intraperitoneal/Peritoneal Dissemination Xenograft
Chemical Information
-
CAS No. 2376783-79-6
-
Masse moléculaire 388.59
-
Formule C21H44N2O4
-
SMILES
CCNC(N[C@H](CO)[C@@H](O)[C@@H](O)CCCCCCCCCCCCCC)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Calculateur de molarité
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
=
×
×
Calculateur de dilution
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
CeY-B1 Related Classifications
HY-188099 Related Classifications
Powered by Bioz